Albrecht Stenzinger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7660439/publications.pdf

Version: 2024-02-01

304 papers	16,802 citations	20817 60 h-index	24258 110 g-index
319 all docs	319 docs citations	319 times ranked	22591 citing authors

#	Article	IF	Citations
1	Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling. Seminars in Cancer Biology, 2022, 84, 129-143.	9.6	41
2	Trailblazing precision medicine in Europe: A joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Seminars in Cancer Biology, 2022, 84, 242-254.	9.6	22
3	Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 251-265.	4.2	22
4	Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 8.e11-8.e18.	1.6	8
5	Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. Genes Chromosomes and Cancer, 2022, 61, 303-313.	2.8	15
6	Cutaneous epithelioid haemangiomas show somatic mutations in the mitogenâ€activated protein kinase pathway. British Journal of Dermatology, 2022, 186, 553-563.	1.5	3
7	The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients. Gastroenterology, 2022, 162, 907-919.e10.	1.3	27
8	Fusionâ€positive nonâ€small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications. Genes Chromosomes and Cancer, 2022, 61, 244-260.	2.8	32
9	TP53 co-mutations as an independent prognostic factor in 2nd and further line therapyâ€”EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. Translational Lung Cancer Research, 2022, 11, 4-13.	2.8	13
10	Homologous Recombination Deficiency: Concepts, Definitions, and Assays. Oncologist, 2022, 27, 167-174.	3.7	69
11	Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genetics in Medicine, 2022, 24, 986-998.	2.4	55
12	Histological and Molecular Plasticity of ALK-positive Non-Small-Cell Lung Cancer under Targeted Therapy - a Case Report. Journal of Physical Education and Sports Management, 2022, , mcs.a006156.	1.2	5
13	Impact of Surgeonâ€™s Experience in Rigid Versus Elastic MRI/TRUS-Fusion Biopsy to Detect Significant Prostate Cancer Using Targeted and Systematic Cores. Cancers, 2022, 14, 886.	3.7	3
14	<scp>Homologous recombination deficiency</scp> is inversely correlated with <scp>microsatellite instability</scp> and identifies immunologically cold tumors in most cancer types. Journal of Pathology: Clinical Research, 2022, 8, 371-382.	3.0	10
15	p53 partial loss-of-function mutations sensitize to chemotherapy. Oncogene, 2022, 41, 1011-1023.	5.9	28
16	Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary. Genes Chromosomes and Cancer, 2022, 61, 551-560.	2.8	4
17	The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. European Journal of Cancer, 2022, 170, 106-118.	2.8	15
18	Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib. Cancers, 2022, 14, 2720.	3.7	5

#	Article	IF	Citations
19	Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC WithÂHighÂProgrammed Death-Ligand 1ÂExpression. JTO Clinical and Research Reports, 2022, 3, 100369.	1.1	3
20	Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). Npj Precision Oncology, 2022, 6, .	5.4	23
21	Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. European Urology Focus, 2021, 7, 102-110.	3.1	28
22	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer, 2021, 152, 174-184.	2.0	53
23	Simulated clinical deployment of fully automatic deep learning for clinical prostate MRI assessment. European Radiology, 2021, 31, 302-313.	4.5	24
24	<scp>PARP</scp> inhibition in prostate cancer. Genes Chromosomes and Cancer, 2021, 60, 344-351.	2.8	2
25	Comparison of Prostate MRI Lesion Segmentation Agreement Between Multiple Radiologists and a Fully Automatic Deep Learning System. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2021, 193, 559-573.	1.3	18
26	Novel GATA6-FOXO1 fusions in a subset of epithelioid hemangioma. Modern Pathology, 2021, 34, 934-941.	5.5	27
27	Ruxolitinib is effective in the treatment of a patient with refractory Tâ€ALL. EJHaem, 2021, 2, 139-142.	1.0	4
28	Integrating proteomics into precision oncology. International Journal of Cancer, 2021, 148, 1438-1451.	5.1	15
29	The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies. European Urology Focus, 2021, 7, 325-331.	3.1	34
30	Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199650.	3.2	24
31	Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Research, 2021, 31, 448-460.	5.5	215
32	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. OncoImmunology, 2021, 10, 1860586.	4.6	40
33	Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets. Cell, 2021, 184, 571-573.	28.9	3
34	Homologous recombination repair deficiency (HRD): From biology to clinical exploitation. Genes Chromosomes and Cancer, 2021, 60, 299-302.	2.8	16
35	Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future. ESMO Open, 2021, 6, 100024.	4.5	13
36	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. Journal of Pathology: Clinical Research, 2021, 7, 311-325.	3.0	19

#	Article	IF	Citations
37	Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. Journal of Medical Internet Research, 2021, 23, e23436.	4.3	36
38	SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nature Metabolism, 2021, 3, 149-165.	11.9	378
39	Morphological and molecular breast cancer profiling through explainable machine learning. Nature Machine Intelligence, 2021, 3, 355-366.	16.0	72
40	KRAS / GNAS â€testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasoundâ€guided workup of suspected mucinous neoplasms of the pancreas. Genes Chromosomes and Cancer, 2021, 60, 489-497.	2.8	13
41	Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. Frontiers in Endocrinology, 2021, 12, 643328.	3.5	12
42	Primary neoplasms of the parapharyngeal space: diagnostic and therapeutic pearls and pitfalls. European Archives of Oto-Rhino-Laryngology, 2021, 278, 4933-4941.	1.6	10
43	Comparison of single-scanner single-protocol quantitative ADC measurements to ADC ratios to detect clinically significant prostate cancer. European Journal of Radiology, 2021, 136, 109538.	2.6	7
44	Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report. Case Reports in Oncology, 2021, 14, 477-482.	0.7	8
45	De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 640048.	2.8	4
46	CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer. JCO Precision Oncology, 2021, 5, 676-686.	3.0	20
47	KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer, 2021, 154, 51-61.	2.0	43
48	<scp>RREB1â€MKL2</scp> fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site?. Genes Chromosomes and Cancer, 2021, 60, 565-570.	2.8	10
49	Targeting rare and non-canonical driver variants in NSCLC â€“ An uncharted clinical field. Lung Cancer, 2021, 154, 131-141.	2.0	8
50	Recurrent YAP1-TFE3 Gene Fusions in Clear Cell Stromal Tumor of the Lung. American Journal of Surgical Pathology, 2021, 45, 1541-1549.	3.7	16
51	Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.	2.8	6
52	Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 670483.	2.8	10
53	Deconvolution of sarcoma methylomes reveals varying degrees of immune cell infiltrates with association to genomic aberrations. Journal of Translational Medicine, 2021, 19, 204.	4.4	5
54	Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies. Translational Lung Cancer Research, 2021, 10, 2118-2131.	2.8	16

#	Article	IF	Citations
55	Knowledge bases and software support for variant interpretation in precision oncology. Briefings in Bioinformatics, 2021, 22, .	6.5	9
56	Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers, 2021, 13, 2616.	3.7	8
57	Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples. BMC Cancer, 2021, 21, 486.	2.6	21
58	Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. BMC Cancer, 2021, 21, 743.	2.6	3
59	SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report. Diagnostic Pathology, 2021, 16, 52.	2.0	6
60	Fully Automatic Deep Learning in Bi-institutional Prostate Magnetic Resonance Imaging. Investigative Radiology, 2021, 56, 799-808.	6.2	27
61	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discovery, 2021, 11, 2780-2795.	9.4	125
62	Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 703893.	2.8	33
63	Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer. ESMO Open, 2021, 6, 100161.	4.5	9
64	Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance. Journal of Clinical Medicine, 2021, 10, 2458.	2.4	3
65	Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 247-255.	2.8	5
66	Comprehensive Dissection of Treatment Patterns and Outcome for Patients With Metastatic Large-Cell Neuroendocrine Lung Carcinoma. Frontiers in Oncology, 2021, 11, 673901.	2.8	8
67	Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder. Scientific Reports, 2021, 11, 14244.	3.3	9
68	Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Translational Lung Cancer Research, 2021, 10, 3093-3105.	2.8	23
69	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. Modern Pathology, 2021, 34, 2122-2129.	5.5	17
70	Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. Journal of Thoracic Oncology, 2021, 16, 1952-1958.	1.1	32
71	Abstract 449: A standard operating procedure for the curation of gene fusions. , 2021, , .		0
72	Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis. Journal of Molecular Diagnostics, 2021, 23, 882-893.	2.8	2

#	Article	IF	Citations
73	Precision oncology: a clinical and patient perspective. Future Oncology, 2021, 17, 3995-4009.	2.4	22
74	High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. British Journal of Dermatology, 2021, , .	1.5	6
75	Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. Cancers, 2021, 13, 4127.	3.7	7
76	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathologica, 2021, 142, 1065-1069.	7.7	16
77	Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open, 2021, 6, 100254.	4.5	35
78	The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. ESMO Open, 2021, 6, 100253.	4.5	17
79	Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Annals of Oncology, 2021, 32, 1626-1636.	1.2	86
80	Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. European Journal of Cancer, 2021, 157, 179-189.	2.8	13
81	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
82	Laboratory-Developed Tests in the New European Union 2017/746 Regulation: Opportunities and Risks. Clinical Chemistry, 2021, 68, 40-42.	3.2	11
83	Prolonged Survival of a Patient with Advanced-Stage Combined Hepatocellular-Cholangiocarcinoma. Case Reports in Gastroenterology, 2021, 14, 658-667.	0.6	6
84	Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302	4.5	6
85	Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. Npj Precision Oncology, 2021, 5, 100.	5.4	21
86	Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Diseaseâ€"A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy. European Urology Focus, 2020, 6, 1205-1212.	3.1	39
87	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene, 2020, 39, 814-832.	5.9	19
88	Patients Resistant Against PSMA-Targeting Î±-Radiation Therapy Often Harbor Mutations in DNA Damage-Repairâ€"Associated Genes. Journal of Nuclear Medicine, 2020, 61, 683-688.	5.0	61
89	Testing NTRK testing: Wetâ€lab and in silico comparison of RNAâ€based targeted sequencing assays. Genes Chromosomes and Cancer, 2020, 59, 178-188.	2.8	52
90	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. Hepatology, 2020, 72, 1253-1266.	7.3	42

#	Article	IF	Citations
91	Primary pulmonary myxoid sarcoma with an unusual gene fusion between exon 7 of EWSR1 and exon 5 of CREB1. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 787-791.	2.8	7
92	Rearranged ERG confers robustness to prostate cancer cells by subverting the function of p53. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 736.e1-736.e10.	1.6	2
93	Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives. Translational Lung Cancer Research, 2020, 9, 1000-1014.	2.8	9
94	Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing. Lung Cancer, 2020, 148, 105-112.	2.0	26
95	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2020, 31, 1491-1505.	1.2	658
96	Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. EBioMedicine, 2020, 62, 103103.	6.1	32
97	EWSR1/FUSâ€“CREB fusions define a distinctive malignant epithelioid neoplasm with predilection for mesothelial-lined cavities. Modern Pathology, 2020, 33, 2233-2243.	5.5	49
98	Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence. Cancer Cell, 2020, 38, 624-625.	16.8	35
99	Successful BRAF/MEK inhibition in a patient with BRAF^{V600E}-mutated extrapancreatic acinar cell carcinoma. Journal of Physical Education and Sports Management, 2020, 6, a005553.	1.2	13
100	Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer Subtypes. Cancers, 2020, 12, 2704.	3.7	13
101	Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. Journal of Cancer, 2020, 11, 6081-6089.	2.5	8
102	Adaptive Immunity and Pathogenesis of Diabetes: Insights Provided by the Î±4â€“Integrin Deficient NOD Mouse. Cells, 2020, 9, 2597.	4.1	4
103	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discovery, 2020, 10, 1808-1825.	9.4	388
104	The landscape of chromothripsis across adult cancer types. Nature Communications, 2020, 11, 2320.	12.8	75
105	Distinct immune evasion in <scp>APOBEC</scp>â€enriched, <scp>HPV</scp>â€negative <scp>HNSCC</scp>. International Journal of Cancer, 2020, 147, 2293-2302.	5.1	10
106	Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group â€˜Molecular Diagnostics and Therapyâ€™. European Journal of Cancer, 2020, 135, 1-7.	2.8	23
107	Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer. Cancers, 2020, 12, 1604.	3.7	63
108	Immunoâ€oncology gene expression profiling of formalinâ€fixed and paraffinâ€embedded clear cell renal cell carcinoma: Performance comparison of the <scp>NanoString nCounter</scp> technology with targeted <scp>RNA</scp> sequencing. Genes Chromosomes and Cancer, 2020, 59, 406-416.	2.8	10

#	Article	IF	Citations
109	Automated sample preparation with <scp>SP</scp> 3 for lowâ€input clinical proteomics. Molecular Systems Biology, 2020, 16, e9111.	7.2	133
110	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations ofÂtheÂQuality in Pathology Study. Journal of Thoracic Oncology, 2020, 15, 1177-1189.	1.1	81
111	Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATAâ€binding protein 3 in nonâ€smallâ€cell lung cancer. Histopathology, 2020, 77, 900-914.	2.9	6
112	Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. Pancreatology, 2020, 20, 425-432.	1.1	11
113	Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement. Lung Cancer, 2020, 142, 114-119.	2.0	28
114	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. Gastroenterology, 2020, 158, 1326-1333.	1.3	60
115	Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. International Journal of Cancer, 2020, 146, 3053-3064.	5.1	14
116	Endometrial stromal sarcomas with BCORâ€rearrangement harbor MDM2 amplifications. Journal of Pathology: Clinical Research, 2020, 6, 178-184.	3.0	32
117	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. , 2020, 8, e000147.		329
118	<scp>NTRK</scp> testing: First results of the <scp>QuiPâ€EQA</scp> scheme and a comprehensive map of <scp>NTRK</scp> fusion variants and their diagnostic coverage by targeted <scp>RNA</scp>â€based <scp>NGS</scp> assays. Genes Chromosomes and Cancer, 2020, 59, 445-453.	2.8	27
119	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. Trials, 2020, 21, 352.	1.6	7
120	High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naÃ¯ve metastatic prostate cancer â€“Results from a prospective pilot study using a 37 gene panel. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e17-637.e27.	1.6	12
121	Evaluation of a Hybrid Captureâ€“Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes. Journal of Molecular Diagnostics, 2020, 22, 757-769.	2.8	42
122	Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma. American Journal of Surgical Pathology, 2020, 44, 1677-1684.	3.7	51
123	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. Journal of Clinical Investigation, 2020, 130, 2488-2495.	8.2	23
124	Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: The GMMG-Birma Trial. Blood, 2020, 136, 44-45.	1.4	16
125	IMPACT OF DEEP TARGETED NEXT GENERATION SEQUENCING ON THE WORK-UP OF PATIENTS WITH PANCREAS CYSTS OR DILATED DUCT - A PROSPECTIVE STUDY WITH EUS-GUIDED FNA. Endoscopy, 2020, 52, .	1.8	0
126	Clinical and molecular profile of de novo vs. secondary EGFR mutated metastatic non-small-cell lung cancer. Pneumologie, 2020, 74, .	0.1	0

#	Article	IF	Citations
127	Combined Immunohistochemistry after Mass Spectrometry Imaging for Superior Spatial Information. Proteomics - Clinical Applications, 2019, 13, e1800035.	1.6	23
128	KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors â€" TORC1/2 Inhibition as Salvage Strategy. Molecular Cancer Therapeutics, 2019, 18, 1985-1996.	4.1	22
129	Optimizing panel-based tumor mutational burden (TMB) measurement. Annals of Oncology, 2019, 30, 1496-1506.	1.2	123
130	Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment. Radiology, 2019, 293, 607-617.	7.3	214
131	Prediction of significant prostate cancer in biopsy-naÃ¯ve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. PLoS ONE, 2019, 14, e0221350.	2.5	13
132	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1443-1454.	4.2	13
133	RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. Cancers, 2019, 11, 1309.	3.7	32
134	In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. Cancers, 2019, 11, 1271.	3.7	27
135	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	1.1	69
136	The BRCA2 mutation status shapes the immune phenotype of prostate cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1621-1633.	4.2	38
137	Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. Genes Chromosomes and Cancer, 2019, 58, 578-588.	2.8	173
138	Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. Cancers, 2019, 11, 124.	3.7	36
139	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	5.1	76
140	Several genotypes, one phenotype: PIK3CA/AKT1 mutation-negative hidradenoma papilliferum show genetic lesions in other components of the signalling network. Pathology, 2019, 51, 362-368.	0.6	10
141	Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. International Journal of Cancer, 2019, 145, 2963-2973.	5.1	24
142	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clinical Cancer Research, 2019, 25, 3986-3995.	7.0	32
143	Defective homologous recombination DNA repair as therapeutic target in advanced chordoma. Nature Communications, 2019, 10, 1635.	12.8	64
144	Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products. Clinical Chemistry, 2019, 65, 549-558.	3.2	37

#	Article	IF	Citations
145	Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1â€“ALK-rearranged lung cancer. Journal of Physical Education and Sports Management, 2019, 5, a004630.	1.2	13
146	Digital PCR After MALDIâ€“Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma. Proteomics - Clinical Applications, 2019, 13, e1800034.	1.6	19
147	Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFRâ€mutated lung cancer. International Journal of Cancer, 2019, 144, 545-557.	5.1	8
148	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of Oncology, 2019, 30, 44-56.	1.2	1,742
149	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and realâ€life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	5.1	95
150	Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma. Hepatology, 2019, 69, 2091-2106.	7.3	63
151	Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer, 2019, 145, 649-661.	5.1	85
152	Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 2019, 30, 161-165.	1.2	60
153	Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas. International Journal of Cancer, 2019, 144, 1061-1072.	5.1	22
154	Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate. European Radiology, 2019, 29, 1820-1830.	4.5	24
155	Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	5.1	131
156	Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. Genes Chromosomes and Cancer, 2019, 58, 3-11.	2.8	14
157	Identification of a highly lethal V3⁺TP53⁺ subset in ALK⁺ lung adenocarcinoma. International Journal of Cancer, 2019, 144, 190-199.	5.1	67
158	RSPO2 gene rearrangement: a powerful driver of Î²-catenin activation in liver tumours. Gut, 2019, 68, 1287-1296.	12.1	29
159	Defining molecular risk in ALK+ NSCLC. Oncotarget, 2019, 10, 3093-3103.	1.8	35
160	Comparison of different semi-automated cfDNA extraction methods in combination with UMI-based targeted sequencing. Oncotarget, 2019, 10, 5690-5702.	1.8	15
161	MiRNAs involved in development of intraepithelial precursor lesions and progression to cholangiocarcinoma. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
162	Cholangiocarcinogenesis is a developmental process driven by distinct sequential alterations of the cellular transcriptome. , 2019, 57, .		0

#	Article	IF	Citations
163	RSPO2 gene rearrangement â€“ a new cancer driver in the liver. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.5	0
164	TP53 status conversion defines an unfavourable patient subset with inferior overall survival in ALK+ lung adenocarcinoma. , 2019, 73, .		0
165	A framework for risk stratification in EGFR+ lung adenocarcinoma treated with tyrosine kinase inhibitors. , 2019, 73, .		0
166	Nivolumab maintenance after salvage autologous stem cell transplantation results in longâ€term remission in multiple relapsed primary <scp>CNS</scp> lymphoma. European Journal of Haematology, 2018, 101, 115-118.	2.2	19
167	Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders. Leukemia and Lymphoma, 2018, 59, 2660-2669.	1.3	3
168	Three molecular pathways model colorectal carcinogenesis in <scp>L</scp>ynch syndrome. International Journal of Cancer, 2018, 143, 139-150.	5.1	129
169	EML4â€ALK fusion variant V3 is a highâ€risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ nonâ€small cell lung cancer. International Journal of Cancer, 2018, 142, 2589-2598.	5.1	93
170	Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations. Pathology Research and Practice, 2018, 214, 408-416.	2.3	4
171	Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. Pathology, 2018, 50, 327-332.	0.6	27
172	Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix. Modern Pathology, 2018, 31, 829-839.	5.5	44
173	Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nature Communications, 2018, 9, 144.	12.8	197
174	Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. Genes Chromosomes and Cancer, 2018, 57, 70-79.	2.8	19
175	Simultaneous whole-body 18Fâ€“PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 340-347.	6.4	32
176	Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 1002-1011.	2.4	6
177	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clinical Cancer Research, 2018, 24, 351-359.	7.0	81
178	Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. JCO Precision Oncology, 2018, 2, 1-13.	3.0	20
179	Implementing tumor mutational burden (TMB) analysis in routine diagnosticsâ€”a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	2.8	152
180	EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC. Journal of Thoracic Disease, 2018, 10, S1989-S1991.	1.4	26

#	Article	IF	Citations
181	Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations. Lung Cancer, 2018, 126, 80-88.	2.0	16
182	Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology, 2018, 50, 703-710.	0.6	21
183	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. OncoImmunology, 2018, 7, e1526613.	4.6	60
184	NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. Cancer Discovery, 2018, 8, 1087-1095.	9.4	189
185	Molecular dissection of large cell carcinomas of the lung with null immunophenotype. Pathology, 2018, 50, 530-535.	0.6	7
186	Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data. BMC Bioinformatics, 2018, 19, 157.	2.6	4
187	Prostatic metastasis from intrahepatic cholangiocarcinoma. Urology Case Reports, 2018, 20, 90-91.	0.3	4
188	Integrated Histogenetic Analysis Reveals BAP1 -Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 677-682.	4.9	6
189	A field guide for cancer diagnostics using cellâ€free DNA: From principles to practice and clinical applications. Genes Chromosomes and Cancer, 2018, 57, 123-139.	2.8	155
190	Profiling of Oncogenic Signaling in Multiple Myeloma â€" Association with Biology, Disease Progression and Prognosis. Blood, 2018, 132, 3206-3206.	1.4	1
191	Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas. Modern Pathology, 2017, 30, 610-619.	5.5	131
192	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. OncoImmunology, 2017, 6, e1279777.	4.6	50
193	Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia. Blood, 2017, 129, 1333-1342.	1.4	57
194	Chloroquine enhances the antimycobacterial activity of isoniazid and pyrazinamide by reversing inflammation-induced macrophage efflux. International Journal of Antimicrobial Agents, 2017, 50, 55-62.	2.5	15
195	Mutation patterns in genes encoding interferon signaling and antigen presentation: A panâ€cancer survey with implications for the use of immune checkpoint inhibitors. Genes Chromosomes and Cancer, 2017, 56, 651-659.	2.8	35
196	Precision oncology based on omics data: The NCT Heidelberg experience. International Journal of Cancer, 2017, 141, 877-886.	5.1	133
197	Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer. British Journal of Cancer, 2017, 117, 220-226.	6.4	25
198	MiR-200b and miR-155 as predictive biomarkers for the efficacy of chemoradiation in locally advanced head and neck squamous cell carcinoma. European Journal of Cancer, 2017, 77, 3-12.	2.8	51

#	Article	IF	Citations
199	Genomics of Immunotherapy-Associated Hyperprogressorsâ€"Letter. Clinical Cancer Research, 2017, 23, 6374-6375.	7.0	11
200	EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 509-520.	2.8	29
201	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes Chromosomes and Cancer, 2017, 56, 758-766.	2.8	21
202	Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas. International Journal of Cancer, 2017, 141, 1841-1848.	5.1	21
203	Qualitative Comparison Between Carrier-based and Classical Tissue Microarrays. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, e74-e79.	1.2	15
204	Targeted nextâ€generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. Genes Chromosomes and Cancer, 2017, 56, 255-265.	2.8	21
205	Mutations of cancer-related genes in benign tumors: the example of hidradenoma papilliferum. Human Pathology, 2017, 62, 246-247.	2.0	3
206	Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. Genes Chromosomes and Cancer, 2017, 56, 214-220.	2.8	8
207	Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3Kâ€"AKT pathway. Genes Chromosomes and Cancer, 2017, 56, 11-17.	2.8	27
208	PARP inhibition in BRCA2-mutated prostate cancer. Annals of Oncology, 2017, 28, 189-191.	1.2	12
209	Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma. Annals of Oncology, 2017, 28, 142-148.	1.2	30
210	A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol. BMC Cancer, 2017, 17, 576.	2.6	36
211	Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. Oncotarget, 2017, 8, 74049-74057.	1.8	14
212	Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. Oncotarget, 2017, 8, 77897-77914.	1.8	19
213	Implementation of a novel efficacy score to compare sealing and cutting devices in a porcine model. , 2017, 77, .		0
214	Targeting irradiationâ€induced mitogenâ€activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer. Head and Neck, 2016, 38, E2049-61.	2.0	16
215	Mutations in genes encoding <scp>PI3Kâ€AKT</scp> and <scp>MAPK</scp> signaling define anogenital papillary hidradenoma. Genes Chromosomes and Cancer, 2016, 55, 113-119.	2.8	29
216	Highâ€throughput diagnostic profiling of clinically actionable gene fusions in lung cancer. Genes Chromosomes and Cancer, 2016, 55, 30-44.	2.8	65

#	Article	IF	Citations
217	Panâ€cancer analysis of copy number changes in programmed deathâ€ligand 1 (PDâ€L1, CD274) â€“ associations with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639.	2.8	80
218	Cadherin-6 is a putative tumor suppressor and target of epigenetically dysregulated miR-429 in cholangiocarcinoma. Epigenetics, 2016, 11, 780-790.	2.7	33
219	Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation. Annals of Oncology, 2016, 27, 2262-2268.	1.2	38
220	Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens. Molecular and Cellular Proteomics, 2016, 15, 3081-3089.	3.8	72
221	Health Care Infrastructure for Financially Sustainable Clinical Genomics. Journal of Molecular Diagnostics, 2016, 18, 697-706.	2.8	15
222	Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report. Diagnostic Pathology, 2016, 11, 133.	2.0	8
223	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Journal of Physical Education and Sports Management, 2016, 2, a001180.	1.2	57
224	Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. Genes Chromosomes and Cancer, 2016, 55, 268-277.	2.8	28
225	Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. Genes Chromosomes and Cancer, 2016, 55, 505-521.	2.8	34
226	Copy number changes of clinically actionable genes in melanoma, nonâ€small cell lung cancer and colorectal cancerâ€”A survey across 822 routine diagnostic cases. Genes Chromosomes and Cancer, 2016, 55, 821-833.	2.8	43
227	NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 697-705.	2.8	24
228	Individualized medicine and demographic change as determining workload factors in pathology: quo vadis?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 101-108.	2.8	19
229	CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nature Medicine, 2016, 22, 278-287.	30.7	184
230	The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability. Oncogene, 2016, 35, 2398-2406.	5.9	22
231	Molecular driver alterations and their clinical relevance in cancer of unknown primary site. Oncotarget, 2016, 7, 44322-44329.	1.8	47
232	Role ofTP53mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget, 2016, 7, 67686-67698.	1.8	50
233	Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment. Oncotarget, 2016, 7, 13236-13247.	1.8	23
234	Genetic changes of non-small cell lung cancer under neoadjuvant therapy. Oncotarget, 2016, 7, 29761-29769.	1.8	16

#	Article	IF	Citations
235	Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. Radiation Oncology, 2015, 10, 146.	2.7	14
236	Basket Trials: Just the End of the First Quarter. Journal of Clinical Oncology, 2015, 33, 2823-2824.	1.6	15
237	Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breastâ€"implications for tumor biology and pathological diagnosis. Genes Chromosomes and Cancer, 2015, 54, 444-452.	2.8	55
238	Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer. American Journal of Surgical Pathology, 2015, 39, 1140-1147.	3.7	35
239	The landscape of metastatic progression patterns across major human cancers. Oncotarget, 2015, 6, 570-583.	1.8	208
240	Establishment of a patient-derived orthotopic osteosarcoma mouse model. Journal of Translational Medicine, 2015, 13, 136.	4.4	35
241	Semiconductorâ€Based Sequencing of Formalinâ€Fixed, Paraffinâ€Embedded Colorectal Cancer Samples. Oncologist, 2015, 20, e10-1.	3.7	10
242	Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence. European Journal of Cancer, 2015, 51, 514-521.	2.8	75
243	CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. Journal of Translational Medicine, 2015, 13, 106.	4.4	11
244	Prognostic Impact and Clinicopathological Correlations of the Cribriform Pattern in Pulmonary Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, 638-644.	1.1	83
245	Allelic Ratio of KRAS Mutations in Pancreatic Cancer. Oncologist, 2015, 20, e8-e9.	3.7	36
246	Loss of SOX2 expression induces cell motility via vimentin upâ€regulation and is an unfavorable risk factor for survival ofÂhead and neck squamous cell carcinoma. Molecular Oncology, 2015, 9, 1704-1719.	4.6	60
247	Classical pathology and mutational load of breast cancer â€“ integration of two worlds. Journal of Pathology: Clinical Research, 2015, 1, 225-238.	3.0	91
248	Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. British Journal of Cancer, 2015, 113, 1343-1349.	6.4	54
249	Histological tumor typing in the age of molecular profiling. Pathology Research and Practice, 2015, 211, 897-900.	2.3	10
250	ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making. Lung Cancer, 2015, 90, 465-471.	2.0	36
251	GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma. Oncotarget, 2015, 6, 4516-4526.	1.8	22
252	EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. European Respiratory Journal, 2014, 43, 872-883.	6.7	97

#	Article	IF	Citations
253	BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Modern Pathology, 2014, 27, 1028-1034.	5.5	96
254	KIT mutations in primary mediastinal B-cell lymphoma. Blood Cancer Journal, 2014, 4, e241-e241.	6.2	2
255	Increased microtubule assembly rates influence chromosomal instability in colorectal cancer cells. Nature Cell Biology, 2014, 16, 779-791.	10.3	174
256	Cancer beyond organ and tissue specificity: Nextâ€generationâ€sequencing gene mutation data reveal complex genetic similarities across major cancers. International Journal of Cancer, 2014, 135, 2362-2369.	5.1	36
257	Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Hepatology, 2014, 59, 544-554.	7.3	97
258	KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma. Pancreas, 2014, 43, 578-583.	1.1	36
259	<scp>ROS</scp>1 expression and translocations in nonâ€smallâ€cell lung cancer: clinicopathological analysis of 1478 cases. Histopathology, 2014, 65, 187-194.	2.9	96
260	Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer. Journal of Clinical Pathology, 2014, 67, 482-490.	2.0	13
261	Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. British Journal of Cancer, 2014, 111, 1222-1229.	6.4	114
262	Mutations in POLE and survival of colorectal cancer patients â€“ link to disease stage and treatment. Cancer Medicine, 2014, 3, 1527-1538.	2.8	56
263	Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study. European Archives of Oto-Rhino-Laryngology, 2014, 271, 1715-1722.	1.6	16
264	The DNA index is a strong predictive marker in intrahepatic cholangiocarcinoma: the results of a five-year prospective study. Surgery Today, 2014, 44, 1336-1342.	1.5	12
265	The combinatorial complexity of cancer precision medicine. Oncoscience, 2014, 1, 504-509.	2.2	48
266	Potential clinical implications ofBRAFmutations in histiocytic proliferations. Oncotarget, 2014, 5, 4060-4070.	1.8	78
267	Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm. Oncotarget, 2014, 5, 6404-6413.	1.8	82
268	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. Oncotarget, 2014, 5, 8147-8160.	1.8	83
269	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget, 2014, 5, 9952-9965.	1.8	58
270	Molecular Diagnostic Profiling of Lung Cancer Specimens with a Semiconductor-Based Massive Parallel Sequencing Approach. Journal of Molecular Diagnostics, 2013, 15, 765-775.	2.8	107

#	Article	IF	Citations
271	Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model. Strahlentherapie Und Onkologie, 2013, 189, 957-966.	2.0	14
272	Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotechnology, 2013, 31, 539-544.	17.5	920
273	Follicleâ€stimulating hormone receptor expression in soft tissue sarcomas. Histopathology, 2013, 63, 29-35.	2.9	16
274	Correlation of radio- and histomorphological pattern of pulmonary adenocarcinoma. European Respiratory Journal, 2013, 41, 943-951.	6.7	105
275	DNA Index as a Strong Prognostic Factor in Patients With Adenocarcinoma of the Pancreatic Head. Pancreas, 2013, 42, 807-812.	1.1	14
276	Fibroblast Growth Factor Receptor 1 as a Putative Therapy Target in Colorectal Cancer. Digestion, 2013, 88, 172-181.	2.3	25
277	Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. British Journal of Cancer, 2013, 109, 2665-2674.	6.4	209
278	High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer, 2013, 13, 450.	2.6	63
279	Survival of Patients with Oral Cavity Cancer in Germany. PLoS ONE, 2013, 8, e53415.	2.5	69
280	Absence Of BRAF and KRAS Hotspot Mutations In Primary Mediastinal and Other Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 4325-4325.	1.4	0
281	Prolyl Hydroxylase Domain 2 Protein Is a Strong Prognostic Marker in Human Gastric Cancer. Pathobiology, 2012, 79, 11-17.	3.8	13
282	Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas. European Respiratory Journal, 2012, 40, 1221-1227.	6.7	97
283	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood, 2012, 120, e28-e34.	1.4	199
284	Quantitative Analysis of Diagnostic Guidelines for HER2-Status Assessment. Journal of Molecular Diagnostics, 2012, 14, 199-205.	2.8	18
285	The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival. Journal of Clinical Oncology, 2012, 30, 1438-1446.	1.6	606
286	Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 185-193.	2.8	55
287	Reversion-inducing cysteine-rich protein with Kazal motif (RECK) expression: an independent prognostic marker of survival in colorectal cancer. Human Pathology, 2012, 43, 1314-1321.	2.0	15
288	High extracellular matrix metalloproteinase inducer/CD147 expression is strongly and independently associated with poor prognosis in colorectal cancer. Human Pathology, 2012, 43, 1471-1481.	2.0	30

#	Article	IF	Citations
289	Postoperative Complications Deteriorate Long-Term Outcome in Pancreatic Cancer Patients. Annals of Surgical Oncology, 2012, 19, 856-863.	1.5	78
290	Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 299-308.	2.8	60
291	Visceral leishmaniasis in a patient with AIDS: early pathological diagnosis using conventional histology, PCR and electron microscopy is the key for adequate treatment. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 357-360.	2.8	5
292	High nuclear polyâ€(ADPâ€ribose)â€polymerase expression is prognostic of improved survival in pancreatic cancer. Histopathology, 2012, 61, 409-416.	2.9	31
293	Downâ€regulation of the microRNA processing enzyme Dicer is a prognostic factor in human colorectal cancer. Histopathology, 2012, 61, 552-561.	2.9	44
294	Who Is at Risk for Diagnostic Discrepancies? Comparison of Pre- and Postmortal Diagnoses in 1800 Patients of 3 Medical Decades in East and West Berlin. PLoS ONE, 2012, 7, e37460.	2.5	53
295	The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). Annals of Oncology, 2011, 22, 1878-1885.	1.2	112
296	Decreased RECK and Increased EMMPRIN Expression in Urothelial Carcinoma of the Bladder Are Associated with Tumor Aggressiveness. Pathobiology, 2011, 78, 123-131.	3.8	13
297	Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximabâ€“Docetaxel Treatment. Clinical Cancer Research, 2011, 17, 5197-5204.	7.0	85
298	mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer, 2011, 18, 181-192.	3.1	90
299	KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics. Journal of Molecular Diagnostics, 2010, 12, 35-42.	2.8	94
300	Chapter 6 Cell and Molecular Biology of the Novel Protein Tyrosineâ€Phosphataseâ€Interacting Protein 51. International Review of Cell and Molecular Biology, 2009, 275, 183-246.	3.2	25
301	Expression profile of PTPIP51 in mouse brain. Journal of Comparative Neurology, 2009, 517, 892-905.	1.6	18
302	The novel protein PTPIP51 is expressed in human keratinocyte carcinomas and their surrounding stroma. Journal of Cellular and Molecular Medicine, 2008, 12, 2083-2095.	3.6	16
303	Epidermal Growth Factor-, Transforming Growth Factor-Î²-, Retinoic Acid- and 1,25-Dihydroxyvitamin D₃-Regulated Expression of the Novel Protein PTPIP51 in Keratinocytes. Cells Tissues Organs, 2006, 184, 76-87.	2.3	21
304	The novel protein PTPIP51 exhibits tissue- and cell-specific expression. Histochemistry and Cell Biology, 2005, 123, 19-28.	1.7	26